53BP2 was initially identi®ed as a protein interacting with p53 in a yeast two-hybrid screen and subsequently shown to enhance p53 transcriptional transactivation and induce apoptosis when transiently overexpressed in cell lines. In order to further study the biologically relevant eects of 53BP2, we have constructed HEK293 stable cell lines where 53BP2 expression can be regulated using an ecdysone inducible expression system. Our results indicate that the response of cells is dependent on the amount of 53BP2 that is expressed. High levels of 53BP2 expression (5140-fold above endogenous) impede cell cycle progression and induce apoptosis. Lower levels of 53BP2 expression (6 ± 11-fold above endogenous) suppress colony formation but do not lead to detectable perturbations in the cell cycle or apoptosis. Lower levels of 53BP2 expression sensitized cells to apoptosis induced by DNA damaging chemotherapy agents doxorubicin, ara-C and VP16, but not microtubule active agents paclitaxel and vinblastine. Our results demonstrate that high levels of 53BP2 expression have profound biological eects ultimately leading to apoptosis, whereas lower levels of 53BP2 expression have more subtle eects on growth and sensitize cells to some chemotherapy agents. Oncogene (2001) 20, 2720 ± 2725.
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Keywords: 53BP2; p53; apoptosis; doxorubicin; paclitaxel 53BP2 was initially isolated as a protein interacting with wild-type but not mutant forms of p53 in yeast two-hybrid screens (Iwabuchi et al., 1994) . p53 is a multifunctional protein which regulates cellular pathways of apoptosis and G1 and G2/M cell cycle arrest (Chen et al., 1996; el-Deiry et al., 1993; Hermeking et al., 1997; Levine, 1997) . 53BP2 was also shown to interact with other proteins including protein phosphatase 1 (PP1) (Helps et al., 1995) , Bcl-2 (Naumovski and Cleary, 1996) , and NF-kB subunit p65 (Yang et al., 1999) . 53BP2 has four ankyrin repeats and a src homology 3 domain that are required for interaction with p53 (Naumovski and Cleary, 1996) . The crystal structure of p53 bound to the ankyrin and SH3 domains of 53BP2 reveals that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved amino acids that are frequently mutated in cancer (Gorina and Pavletich, 1996) . 53BP2 is a cytoplasmic protein (Naumovski and Cleary, 1996) found in low levels in a variety of normal human tissues and cell lines (our unpublished data). Our previous studies have shown that 53BP2 impedes cell cycle progression in transient transfection assays and stable clones constitutively expressing 53BP2 cannot be constructed (Naumovski and Cleary, 1996) . Transient overexpression of 53BP2 was also shown to enhance p53-mediated transcriptional transactivation (Iwabuchi et al., 1998) and induce apoptosis (Yang et al., 1999) . However, due to massive overexpression of the protein in transient transfection assays, the biological relevance of the observed eects of 53BP2 is unclear.
To investigate the eects of regulated expression of 53BP2, we constructed 53BP2 inducible HEK293 cell lines using an ecdysone inducible expression system. A BamHI ± XbaI fragment of 53BP2 was cloned into an ecdysone-inducible expression vector pIND and transfected into HEK293 cells containing the ecdysone receptor (EcR293). A pIND-LacZ vector was used to make a control cell line. Several clones that express 53BP2 or LacZ upon treatment with ponasterone A (Pon A), an ecdysone analogue used as an inducing agent, were identi®ed and puri®ed. Two 53BP2 inducible clones with 595% purity were used for further studies. Levels of 53BP2 were determined by Western blotting extracts from the LacZ inducible cell line (LacZ/293) and two 53BP2 inducible cell lines (53BP2/293-c1 and 53BP2/293-c2) 24 h after Pon A induction with an anti-53BP2 antibody (Figure 1a) . Low levels of endogenous 53BP2 were detected in both the LacZ inducible cell line and the two 53BP2 inducible cell lines. Levels of 53BP2 did not change in the LacZ inducible cell line but increased signi®-cantly in both 53BP2 inducible cell lines upon Pon A treatment (Figure 1a) . When the levels of 53BP2 were quantitated and normalized to tubulin (Figure 1a) , the 53BP2/293-c1 clone expressed levels of 6-and 11-fold Current address: School of Natural and Applied Sciences, University of Houston-Clear Lake, 2700 Bay Area Blvd., Houston, TX 77058, USA above that of endogenous at doses of 0.5 and 1 mM Pon A. The 53BP2/293-c2 clone expressed levels of 3-and 6.5-fold above that of endogenous at doses of 2.5 and 5 mM Pon A (Figure 1a) . The 53BP2/293-c2 clone was less responsive to Pon A stimulation, requiring a 10-fold higher dose of Pon A to attain a similar level of 53BP2 expression (Figure 1a ). Higher doses of Pon A (up to 5 mM) caused massive overexpression of 53BP2 in the 53BP2/293-c1 cells (up to 140-fold over the endogenous level, data not shown). The level of 53BP2 expression induced by higher doses of Pon A (5 mM) eectively mimics the amount of 53BP2 protein obtained in transient transfections, where the transient transfection eciency was about 25% as determined by immuno¯uorescence microscopy ( Figure 1b) . Further experiments were done to examine the eects of regulated expression of 53BP2 at both`high' (5140-fold over endogenous) and`low' (6 ± 11-fold above endogenous) levels of expression through titration of the Pon A concentration.
In order to determine the eects of high 53BP2 expression on cell survival, we treated 53BP2/293-c1 cells and LacZ/293 cells with 5 mM Pon A or ethanol and determined clonogenic survival. We found the clonogenic survival of 53BP2/293-c1 was less than 5% in the presence of Pon A compared to the absence of Pon A whereas the clonogenic survival of the LacZ/293 cells was approximately 90% in the presence of Pon A compared to the absence of Pon A (data not shown). To determine more precisely the eects of lower expression of 53BP2 and the length of time 53BP2 needed to be expressed before cells committed to die, we treated 53BP2/293-c1 cells and LacZ/293 cells with 0, 0.5 or 1 mM Pon A for either 0, 1, 2, 3, 6 or 12 days. A dramatic loss of colony forming ability was noted when cells were treated with Pon A for as little as 1 ± 2 days ( Figure 2a ). The higher dose of Pon A (1 mM), which induced 53BP2 protein approximately 11-fold above the endogenous level (Figure 1a ), resulted in an almost 50% decrease in colony formation 1 day after induction, whereas with the lower dose of Pon A (0.5 mM), which induced 53BP2 protein approximately sixfold above the endogenous level (Figure 1a) , it took about 2 days to achieve a similar eect (Figure 2a ). These results demonstrate that commitment to death occurs relatively early after controlled 53BP2 expression and that time to commit to death is dependent on 53BP2 levels (see Figure 1 for Pon A dose titration). The commitment to death is an extended process since even after 6 days of Pon A treatment, some cells (10 ± 30%) can still form colonies; this may be due to heterogeneous levels of 53BP2 expression with the cells expressing the most protein dying at the earliest time points. Constitutive expression of 53BP2 by Pon A for 12 days resulted in few colonies. The surviving colonies are most likely 53BP2 non-expressing cells that account for less than 5% of the cell population. Pon A led to only a slight decrease in the formation of colonies by LacZ/293 cells (Figure 2b ). The second 53BP2 inducible clone (53BP2/293-c2) showed similar ®ndings ± 3) , 53BP2/293-c1 (lanes 4 ± 6), and 53BP2/293-c2 (lanes 7 ± 9) cells were treated with the indicated concentrations (mM) of Pon A for 24 h. Cell lysates were prepared in 50 mM TrisCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholic acid, 1.0% NP-40, and a cocktail of protease inhibitors, centrifuged at 13 000 r.p.m. for 10 min, quantitated and 50 mg of total protein was used to detect 53BP2 protein by standard Western blotting techniques using a mouse anti-53BP2 antibody. 53BP2 bands were quantitated utilizing a Biorad scanning densitometer (GS-710) and Molecular Analysis software, normalized to tubulin, and expressed as fold increase compared to 53BP2 levels in cells treated without Pon A. (b) 53BP2-c1 cells (lane 1) were treated with 5 mM of Pon A for 24 h. 293 cells (lane 2) were transfected with 5 mg of 53BP2 expressing plasmid pCMV-53BP2 and harvested 48 h after transfection. Cell lysates were prepared and Western blotting was performed to detect 53BP2. Bands of 53BP2 were quantitated and normalized to Hsc70. 53BP2 and LacZ inducible cell lines were constructed according to protocols provided by the manufacturer of the Pon A regulated expression vector (Invitrogen) and maintained in Dulbecco's modi®ed Eagle's medium (Gibco ± BRL), supplemented with 0.5 mg/ml G418 (Sigma), 0.5 mg/ml Zeocin (Invitrogen), 100 units of penicillin, 100 mg/ml of streptomycin, 300 mg/ml of L-glutamine and 10% (v/v) heat-inactivated fetal bovine serum (CellGro) at 378C in a humidi®ed atmosphere of 95% air 5% CO 2 (v/v) except that a higher dose of Pon A (5 mM) was utilized to achieve a level of 53BP2 expression similar to that in 53BP2/293-c1 clone treated with 0.5 mM Pon A (data not shown).
Our previous work suggested that transient transfection of 53BP2 into 293 cells perturbed the cell cycle (Naumovski and Cleary, 1996). To determine if high level 53BP2 expression perturbs cell cycle progression in the 53BP2 inducible cell line, 53BP2/293-c1 and LacZ/293 cells were not treated or treated with Pon A (5 mM) to induce 53BP2 and LacZ, respectively. After 48 h of Pon A treatment, attached and nonattached cells were collected, pooled and ®xed for cell cycle analysis. No signi®cant dierences in cell cycle pro®le were seen between the LacZ/293 cells treated with Pon A and that without Pon A (data not shown). However, after treatment with Pon A, the percentage of cells in the G1 phase of the cell cycle was decreased from 48 to 33% in the 53BP2/293-c1 cells, while the percentage of cells in the G2/M phase of the cell cycle was increased from 19 to 26%. In addition, we also noted a signi®cant increase in the sub-G0 population of the 53BP2/293-c1 cells, from 2% in the absence of Pon A to 8.6% in the presence of Pon A.
To address the physiological relevance of this eect, we titrated the dose of Pon A to achieve 53BP2 expression 6 ± 11-fold above the endogenous level in 53BP2/293-c1 cells. After growing the cells in Pon A (0.5 or 1 mM) for 48 h, cell cycle pro®les were determined by FACS analysis following propidium iodide staining. Our results did not reveal any signi®cant perturbations in cell cycle (data not shown).
Thus, although 50% of the cells are destined to die as measured by reduction in colony forming potential (Figure 2a) , no cell cycle defects were noted by FACS analysis. The second 53BP2 inducible clone (53BP2/ 293-c2) showed similar results when comparable levels of 53BP2 were obtained using higher doses of Pon A (data not shown).
Visual inspection of Pon A (5 mM) treated 53BP2/ 293-c1 cells suggested that cells were dying compared to non Pon A treated 53BP2/293-c1 cells, whereas LacZ/293 remained viable during Pon A treatment (Figure 3a) . To determine if the cells were dying through apoptosis, we extracted high and low molecular weight DNA from 53BP2/293-c1 and LacZ/293 cells treated with and without Pon A (5 mM) for 48 h. We found that DNA laddering was signi®cantly higher in the 53BP2/293-c1 cells treated with Pon A (Figure 3b ). We also determined that Pon A treated 53BP2/293-c1 cells had apoptotic appearing nuclei as judged by Hoechst staining (data not shown). These results are consistent with previous results obtained from transient transfections (Yang et al, 1999) .
We determined the physiologic relevance of the apoptotic eect of 53BP2 by lowering the levels of 53BP2 expression to 6 ± 11-fold above the endogenous level. 53BP2/293-c1 and 53BP2/293-c2 cells were treated with or without Pon A at doses that induced 53BP2 up to 11-fold above endogenous for 48 h. Apoptotic cells were detected by scoring cells usinḡ uorescence microscopy following Hoechst staining or by determining the sub-G0 fraction of the cells using a ) were treated in triplicates with 0, 0.5 or 1 mM Pon A (dissolved in ethanol) for 0, 1, 2, 3, 6 or 12 days. Equal amounts of ethanol were added to 7Pon A cells as a control. At the end of each time point the media was replaced with fresh media and cells were allowed to grow for a total of 13 days. The resulting colonies were then ®xed, stained with 0.5% crystal violet in 50% ethanol for 30 min, washed three times with water and counted FACScan after propidium iodide staining. We found that the amount of apoptosis in both 53BP2/293-c1 and 53BP2/293-c2 cells treated with Pon A was similar to that of non-Pon A treated cells (data not shown).
Although low levels of 53BP2 expression do not directly cause apoptosis in the 53BP2/293 cell lines, it may sensitize cells to apoptosis induced by chemotherapy drugs. To test this possibility, 53BP2/293-c1 and LacZ/293 cells were treated with various doses of Pon A (0, 0.5, 1 and 2.5 mM) for 24 h and then treated with chemotherapy drugs doxorubicin (a DNA-damaging agent) or paclitaxel (a microtubule-stabilizing agent) for 48 h. Drug concentrations were chosen after pilot experiments were performed to give an approximate equitoxic dose. Expression of B-galactosidase did not signi®cantly in¯uence the survival of cells treated with either doxorubicin or paclitaxel (Figure 4) . However, expression of 53BP2 signi®cantly enhanced apoptosis in the cells treated with doxorubicin but not the cells treated with paclitaxel (Figure 4 ). Sensitization to doxorubicin was apparent at the lowest dose of Pon A used (0.5 mM), where 53BP2 was induced *sixfold above the endogenous level. Further increases in the level of 53BP2 expression by higher doses of Pon A (up to 2.5 mM) showed only a mild further increase in the sensitization, indicating the sensitization eect of 53BP2 is saturable. 53BP2 also sensitized cells to apoptosis induced by DNA-damaging agents ara-C and VP-16 but not microtuble disrupting agent vinblastine (data not shown). Similar results were also obtained in the second 53BP2 inducible clone (53BP2/ 293-c2) when comparable levels of 53BP2 were expressed (data not shown).
Since its discovery as a protein interacting with the tumor suppressor p53, 53BP2 has attracted attention in an attempt to determine its biological functions. Previous ®ndings on the eects of 53BP2 were exclusively based on transient transfection assays where there is a unregulated massive overexpression of nonphysiologic levels of 53BP2 protein. Studies on 53BP2 have been hampered because constitutive expression of 53BP2 suppressed cell growth and stable clones expressing 53BP2 could not be isolated (Naumovski and Cleary, 1996) . In this study, we have successfully established 53BP2 inducible cell lines that enable us to regulate the expression of 53BP2.
In order to determine the biological response of 293 cells to 53BP2 expression, we used both Pon A concentration and time of induction to vary the amount of 53BP2 protein expressed from low levels (6 ± 11-fold above those found endogenously in the 293 cell line) to high levels of expression (5140-fold above endogenous) in our 53BP2 inducible cell lines. The 6 ± 11-fold of induction that we obtained here is 2) and 53BP2/293 (lanes 3 and 4) cells were treated as above, harvested and permeabilized in a Triton X-100 buer to obtain low molecular weight DNA (Hockenbery et al., 1990) . The insoluble pellet was dissolved in SDS detergent buer and total DNA was extracted as described previously (Naumovski and Cleary, 1994) . DNA derived from equivalent numbers of cells was separated by electrophoresis in composite Nusieve-agarose gels physiologically signi®cant because our recent studies have shown that UV irradiation results in 6 ± 14-fold induction of the endogenous 53BP2 protein in GM38 primary human skin ®broblasts and HT 1080 human ®brosarcoma cells (Lopez et al., 2000) . High level expression of 53BP2 protein by higher doses of Pon A, eectively mimics levels achieved after transient transfection of 53BP2. However, we have not been able to ®nd these high levels of 53BP2 protein expression under any physiological circumstances. Our results demonstrate that there are signi®cant dierences in cellular responses between low and high level expression of 53BP2.
We found that 53BP2 levels 6 ± 11-fold above endogenous potently suppressed cell growth in longterm clonogenic survival assays. The time course of loss of colony formation was dependent on both the amount and the duration of 53BP2 protein expression. The higher the level of 53BP2 induced, the less time of expression was needed to attain the same extent of reduction in colony formation, indicating that higher amounts of 53BP2 expression resulted in more rapid dynamics in the reduction of colony formation. However, unlike high amounts of 53BP2 expression (5140-fold above endogenous) which suppress cell growth by impeding cell cycle progression and inducing apoptosis, low levels of 53BP2 expression (6 ± 11-fold above endogenous) do not cause apparent cell cycle perturbation or apoptosis. While our current study cannot rule out subtle eects of low level expression of 53BP2 on cell cycle or/and apoptosis, it is possible that low levels of 53BP2 act through dierent cellular pathways from that of high levels of expression to suppress cell growth. Therefore, some of the eects of 53BP2 that we and others have previously noted may be due to massive overexpression of the protein after transient transfection.
Levels of 53BP2 expression (6 ± 11-fold above endogenous), which did not directly induce apoptosis, sensitized cells to apoptosis induced by DNA-damaging agents doxorubicin, ara-C and VP-16 but not to apoptosis induced by microtubule-acting agents paclitaxel or vinblastine. Further studies on the mechanism by which 53BP2 selectively sensitizes cells to certain chemotherapy agents will be very informative and bring new insights into the biological function of this protein. Finally, our ability to construct 53BP2 inducible cell lines will allow us to establish inducible 53BP2 expression in cell lines with regulated p53 expression and/or null for p53 to determine which eects of 53BP2 are mediated through p53-dependent pathways. Figure 4 Low levels of 53BP2 expression sensitize cells to apoptosis induced by doxorubicin but not paclitaxel. 53BP2/293-c1 and LacZ/293 cells were treated with 0, 0.5, 1, or 2.5 mM of Pon A for 24 h and then with doxorubicin (100 ng/ml) or paclitaxel (100 ng/ ml) for 48 h in the continuous presence of Pon A. The supernatant and trypsin/EDTA treated cells were pelleted by centrifugation at 5000 r.p.m. for 5 min, resuspended in 0.3 ml of PBS, ®xed with 0.7 ml of 100% (v/v) ethanol and incubated overnight at 7208C. Cells were centrifuged at 14 000 r.p.m. for 3 min and resuspended in 0.3 ml of PBS. Ten ml of the cell suspension was mixed with 5 ml of Hoechst stain (Sigma) and apoptotic cells were determined by counting nuclei with morphological changes characteristic of apoptosis using a¯uorescence microscope. A total of 300 cells per sample were counted. The results are shown as the percentage of apoptotic cells with open bars representing cells not treated with chemotherapy drugs and shaded bars representing cells treated with chemotherapy drugs
